NCT00350818View on ClinicalTrials.gov

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Myelodysplastic SyndromeLeukemia
Interventions
DRUG

Azacitidine

8 mg/m\^2 Subcutaneously Once Daily for 5 Days

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER